1353 a Phase Iib Study of the Efficacy and Safety of Lb80380 vs Entecavir in Treatment-Naive Patients With Chronic Hepatitis B

Lai, CL; Ahn, Soo Hyun; Lee, K.S.; Um, Soon-Ho; Cho, M.; Yoon, Soo-Young; Lee, J.W.; Park, N.W.; Kwon, Young Oh; Sohn, Jung Ho; Lee, J.Y.; Park, H.E.; Kim, J.A.; Han, Kyung Hee; Yuen, Man Fung

doi:10.1016/s0168-8278(11)61355-x

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pradefovir (44), invented by Metabasis Therapeutics, is a prodrug that targets adefovir to the liver for the treatment of hepatitis B and is in Phase II clinical trials [114,[120][121]. Besifovir (45, LB80380), invented by LG Chem Ltd, is an acyclic nucleotide phosphonate with chemical similarity to adefovir and tenofovir, which has completed the clinic safety and efficacy study in the patients with lamivudine-refractory chronic hepatitis B, bioequivalence of LB80380 free base and maleate salt tablets and safety and efficacy study of LB80380 in the treatment-naive patients of chronic hepatitis B [122][123][124][125][126][127]. Tenofovir alafenamide (46, TAF; GS-7340), invented by Gilead Sciences, is a prodrug of TDF and achieves higher active metabolite concentrations in peripheral blood mononuclear lymphocytes and lymphatic tissues [128][129][130][131].…”

Section: Inhibitors Of Viral Dna Synthesismentioning

confidence: 99%

Recent Advance of the Hepatitis B Virus Inhibitors: A Medicinal Chemistry Overview

et al. 2015

View full text Add to dashboard Cite

Hepatitis B Virus (HBV) is one of the most prevalent viral infections of human worldwide. The therapies are limited in the clinical context because of negative side effects of interferons and the development of viral resistance to the nucleoside/nucleotide inhibitors. In this review, we summarize the recent advances in design and development of potent anti-HBV inhibitors from natural sources and synthetic compounds, targeting different steps in the life cycle of HBV. We attempt to emphasize the major structural modifications, mechanisms of action and computer-aided docking analysis of novel potent inhibitors that need to be addressed in the future to design potent anti-HBV molecules.

show abstract

Section: Inhibitors Of Viral Dna Synthesismentioning

confidence: 99%

Recent Advance of the Hepatitis B Virus Inhibitors: A Medicinal Chemistry Overview

et al. 2015

View full text Add to dashboard Cite

show abstract

Future Prevention and Treatment of Chronic Hepatitis B Infection

Seto¹,

Fung²,

Yuen

et al. 2012

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Vaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B.

show abstract

Emerging pipeline drugs for hepatitis B infection

Cox¹,

Tillmann²

2011

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Currently, entecavir and tenofovir offer a safe and effective treatment option for patients with chronic HBV with minimal to no resistance. Although entecavir and tenofovir are able to suppress replication in essentially all patients, achieving HBsAg seroconversion remains suboptimal among all antiviral therapy. There are a number of new therapies in the pipeline for the treatment of chronic HBV infection as well as revisiting IFN combined or sequential to antiviral therapy.

show abstract

1353 a Phase Iib Study of the Efficacy and Safety of Lb80380 vs Entecavir in Treatment-Naive Patients With Chronic Hepatitis B

Cited by 3 publications

References 0 publications

Recent Advance of the Hepatitis B Virus Inhibitors: A Medicinal Chemistry Overview

Recent Advance of the Hepatitis B Virus Inhibitors: A Medicinal Chemistry Overview

Future Prevention and Treatment of Chronic Hepatitis B Infection

Emerging pipeline drugs for hepatitis B infection

Contact Info

Product

Resources

About